Studies leading to the identification of ZD1839 (iressa™): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer
Top Cited Papers
- 11 July 2001
- journal article
- research article
- Published by Elsevier BV in Bioorganic & Medicinal Chemistry Letters
- Vol. 11 (14), 1911-1914
- https://doi.org/10.1016/s0960-894x(01)00344-4
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- The Epidermal Growth Factor Receptor and Its Inhibition in Cancer TherapyPharmacology & Therapeutics, 1999
- Epidermal growth factor receptor tyrosine kinase: Structure-activity relationships and antitumour activity of novel quinazolinesBioorganic & Medicinal Chemistry Letters, 1997
- New targets for therapeutic attackEndocrine-Related Cancer, 1997
- STRUCTURE-ACTIVITY RELATIONSHIPS FOR 4-ANILINOQUINAZOLINES AS POTENT INHIBITORS AT THE ATP BINDING SITE OF THE EPIDERMAL GROWTH FACTOR RECEPTOR IN VITROClinical and Experimental Pharmacology and Physiology, 1996
- Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolinesBreast Cancer Research and Treatment, 1996
- Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5'-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor.Journal of Medicinal Chemistry, 1995
- Epidermal growth factor receptor tyrosine kinase: Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitorBiochemical Pharmacology, 1994